Extracellular signal-regulated kinase and Protein kinase B signaling pathway (ERK/AKT signaling)

The Extracellular signal-regulated kinase (ERK) and Protein kinase B (AKT) signaling pathways are two of the most critical intracellular cascades regulating cell growth, survival, and metabolism (Source: NIH). The ERK pathway, part of the Mitogen-Activated Protein Kinase (MAPK) family, primarily responds to growth factors, while the AKT pathway is the central effector of the Phosphoinositide 3-kinase (PI3K) signaling axis (Source: PubMed). These pathways exhibit extensive crosstalk and compensatory mechanisms; for instance, inhibition of the MAPK pathway can lead to the upregulation of PI3K/AKT signaling, contributing to drug resistance in oncology (Source: Nature Reviews Cancer). Dysregulation of this dual axis is a hallmark of numerous malignancies, including melanoma, breast cancer, and colorectal cancer, often driven by mutations in upstream proteins like RAS or BRAF (Source: StatPearls). Consequently, therapeutic strategies frequently focus on dual inhibition or targeting specific nodes like MEK, ERK, PI3K, or AKT to achieve more durable clinical responses. Current clinical applications include the use of MEK inhibitors like trametinib and AKT inhibitors like capivasertib, though management of toxicities such as hyperglycemia and skin rash remains a significant challenge (Source: PubChem).

Other names

MAPK/ERK and PI3K/AKT crosstalkRas-Raf-MEK-ERK and PI3K-AKT-mTOR pathwaysERK/AKT axis

The mechanism of action involves the pharmacological inhibition of specific kinase nodes within the MAPK/ERK and PI3K/AKT cascades. By blocking the phosphorylation of ERK and AKT, drugs prevent the activation of downstream transcription factors and effectors, thereby inhibiting cell cycle progression and inducing apoptosis in malignant cells (Source: PubMed, PMC4351351).